Tomas Kepak

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3089322/publications.pdf

Version: 2024-02-01

		686830	552369
31	768	13	26
papers	citations	h-index	g-index
2.5	2.5	2.5	1150
35	35	35	1158
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Global Retinoblastoma Presentation and Analysis by National Income Level. JAMA Oncology, 2020, 6, 685.	3.4	192
2	Survivorship after childhood cancer: PanCare: A European Network to promote optimal long-term care. European Journal of Cancer, 2015, 51, 1203-1211.	1.3	98
3	Chronic Inflammation in Immune Aging: Role of Pattern Recognition Receptor Crosstalk with the Telomere Complex?. Frontiers in Immunology, 2017, 8, 1078.	2.2	77
4	PanCareLIFE: The scientific basis for a European project to improve long-term care regarding fertility, ototoxicity and health-related quality of life after cancer occurring among children and adolescents. European Journal of Cancer, 2018, 103, 227-237.	1.3	41
5	European PanCareFollowUp Recommendations for surveillance of late effects of childhood, adolescent, and young adult cancer. European Journal of Cancer, 2021, 154, 316-328.	1.3	38
6	Usefulness of current candidate genetic markers to identify childhood cancer patients at risk for platinum-induced ototoxicity: Results of the European PanCareLIFE cohort study. European Journal of Cancer, 2020, 138, 212-224.	1.3	31
7	Genetic variation of cisplatin-induced ototoxicity in non-cranial-irradiated pediatric patients using a candidate gene approach: The International PanCareLIFE Study. Pharmacogenomics Journal, 2020, 20, 294-305.	0.9	28
8	Guidance regarding COVIDâ€19 for survivors of childhood, adolescent, and young adult cancer: A statement from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Pediatric Blood and Cancer, 2020, 67, e28702.	0.8	25
9	Treatment-related fertility impairment in long-term female childhood, adolescent and young adult cancer survivors: investigating dose-effect relationships in a European case-control study (PanCareLIFE). Human Reproduction, 2021, 36, 1561-1573.	0.4	20
10	Travel burden and clinical presentation of retinoblastoma: analysis of 1024 patients from 43 African countries and 518 patients from 40 European countries. British Journal of Ophthalmology, 2021, 105, 1435-1443.	2.1	19
11	The Telomerase Complex Directly Controls Hematopoietic Stem Cell Differentiation and Senescence in an Induced Pluripotent Stem Cell Model of Telomeropathy. Frontiers in Genetics, 2018, 9, 345.	1.1	18
12	The European multistakeholder PanCareFollowUp project: novel, person-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for cancer survivors and caregivers. European Journal of Cancer, 2021, 153, 74-85.	1.3	18
13	The PanCareFollowUp Care Intervention: A European harmonised approach to person-centred guideline-based survivorship care after childhood, adolescent and young adult cancer. European Journal of Cancer, 2022, 162, 34-44.	1.3	17
14	Fertility Among Female Survivors of Childhood, Adolescent, and Young Adult Cancer: Protocol for Two Pan-European Studies (PanCareLIFE). JMIR Research Protocols, 2018, 7, e10824.	0.5	14
15	Genetic variation in gonadal impairment in female survivors of childhood cancer: a PanCareLIFE study protocol. BMC Cancer, 2018, 18, 930.	1.1	13
16	Fertility-Related Wishes and Concerns of Adolescent Cancer Patients and Their Parents. Journal of Adolescent and Young Adult Oncology, 2020, 9, 55-62.	0.7	12
17	Plerixafor combined with standard regimens for hematopoietic stem cell mobilization in pediatric patients with solid tumors eligible for autologous transplants: two-arm phase I/II study (MOZAIC). Bone Marrow Transplantation, 2020, 55, 1744-1753.	1.3	12
18	Determinants of utilization of cryopreservation of germ cells in adolescent cancer patients in four European countries. European Journal of Pediatrics, 2020, 179, 51-60.	1.3	10

#	Article	IF	Citations
19	Genetic Determinants of Ototoxicity During and After Childhood Cancer Treatment: Protocol for the PanCareLIFE Study. JMIR Research Protocols, 2019, 8, e11868.	0.5	10
20	Health-Related Quality of Life in European Childhood Cancer Survivors: Protocol for a Study Within PanCareLIFE. JMIR Research Protocols, 2021, 10, e21851.	0.5	9
21	Adjuvant therapy of histopathological risk factors of retinoblastoma in Europe: A survey by the European Retinoblastoma Group (EURbG). Pediatric Blood and Cancer, 2021, 68, e28963.	0.8	9
22	Childhood cancer survivorship care during the COVID-19 pandemic: an international report of practice implications and provider concerns. Journal of Cancer Survivorship, 2022, 16, 1390-1400.	1.5	9
23	Possible modification of <i>BRSK1</i> on the risk of alkylating chemotherapy-related reduced ovarian function. Human Reproduction, 2021, 36, 1120-1133.	0.4	8
24	TCERG1L allelic variation is associated with cisplatin-induced hearing loss in childhood cancer, a PanCareLIFE study. Npj Precision Oncology, 2021, 5, 64.	2.3	8
25	Effect of Genetic Variation in CYP450 on Gonadal Impairment in a European Cohort of Female Childhood Cancer Survivors, Based on a Candidate Gene Approach: Results from the PanCareLIFE Study. Cancers, 2021, 13, 4598.	1.7	8
26	Childhood survivors of highâ€risk neuroblastoma show signs of immune recovery and not immunosenescence. European Journal of Immunology, 2020, 50, 2092-2094.	1.6	6
27	Fertility education for adolescent cancer patients: Gaps in current clinical practice in Europe. European Journal of Cancer Care, 2020, 29, e13279.	0.7	5
28	Immunosenescence in Childhood Cancer Survivors and in Elderly: A Comparison and Implication for Risk Stratification. Frontiers in Aging, 2021, 2, .	1.2	5
29	Health of children born to childhood cancer survivors: Participant characteristics and methods of the Multicenter Offspring Study. Cancer Epidemiology, 2021, 75, 102052.	0.8	5
30	Association of candidate pharmacogenetic markers with platinum-induced ototoxicity: PanCareLIFE dataset. Data in Brief, 2020, 32, 106227.	0.5	2
31	Assessment of late cardiotoxic effects in patients treated for cancer in childhood. Cancer Medicine, 2022, , .	1.3	1